StockData

Alnylam Pharmaceuticals vs Ionis Pharmaceuticals

ALNY and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and IONS compare

Alnylam Pharmaceuticals is the larger company, worth 4.7 times as much as Ionis Pharmaceuticals ($21.0B against $4.5B).

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −7.4% for Ionis Pharmaceuticals).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −64.7% at Ionis Pharmaceuticals.

Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYIONS
Size and price
Market cap$21.0B$4.5B
Share price$156.50$26.96
Change, 1 year−65.2%−62.3%
Change, 5 years−17.0%−7.2%
Beta (5Y)0.920.60
Employees2,5001,402
StockData Score
Total score10 (better)4
Valuation score3 (better)1
Growth score22
Performance score3 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/E8.1×–
P/S4.2× (better)5.1×
P/B5.8× (better)10.2×
EV/EBITDA16.8×–
P/FCF26.0×–
FCF yield3.8% (better)−12.5%
Fair value$296.91$27.86
Margin of safety47.3% (better)3.2%
Growth
Revenue growth (TTM)56.2% (better)−7.4%
Revenue growth, 5Y average49.8% (better)5.3%
Net income growth (TTM)2137%–
EPS growth (TTM)2308%–
Profitability
Gross margin77.4%98.2% (better)
Operating margin19.5% (better)−68.0%
Net margin52.8% (better)−64.7%
FCF margin16.1% (better)−64.2%
Return on equity127% (better)−105%
Financial health
Interest coverage3.2× (better)−31.6×
Current ratio2.487.89 (better)
Altman Z-score3.62 (better)0.23
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.7%108%
Held by insiders0.49%0.81%
Insider net buying, 12 months−$26.3M (better)−$114M
Superinvestors holding–1
Short interest, % of float4.1%12.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.